Novartis AG (NVS)
97.72
-1.34
(-1.35%)
USD |
NYSE |
Apr 26, 14:46
Novartis Revenue (Quarterly): 12.12B for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.12B |
| December 31, 2023 | 11.78B |
| September 30, 2023 | 12.09B |
| June 30, 2023 | 13.94B |
| March 31, 2023 | 11.05B |
| December 31, 2022 | 10.97B |
| September 30, 2022 | 10.78B |
| June 30, 2022 | 13.08B |
| March 31, 2022 | 12.81B |
| December 31, 2021 | 4.619B |
| September 30, 2021 | 13.37B |
| June 30, 2021 | 13.29B |
| March 31, 2021 | 12.69B |
| December 31, 2020 | 13.03B |
| September 30, 2020 | 12.54B |
| June 30, 2020 | 11.62B |
| March 31, 2020 | 12.71B |
| December 31, 2019 | 12.72B |
| September 30, 2019 | 12.48B |
| June 30, 2019 | 12.02B |
| March 31, 2019 | 11.46B |
| December 31, 2018 | 11.90B |
| September 30, 2018 | 11.39B |
| June 30, 2018 | 11.65B |
| March 31, 2018 | 11.16B |
| Date | Value |
|---|---|
| December 31, 2017 | 6.433B |
| September 30, 2017 | 12.69B |
| June 30, 2017 | 12.49B |
| March 31, 2017 | 11.78B |
| December 31, 2016 | 12.61B |
| September 30, 2016 | 12.34B |
| June 30, 2016 | 12.68B |
| March 31, 2016 | 11.81B |
| December 31, 2015 | 12.80B |
| September 30, 2015 | 12.48B |
| June 30, 2015 | 12.90B |
| March 31, 2015 | 12.20B |
| December 31, 2014 | 13.35B |
| September 30, 2014 | 13.30B |
| June 30, 2014 | 13.95B |
| March 31, 2014 | 13.03B |
| December 31, 2013 | 13.63B |
| September 30, 2013 | 12.91B |
| June 30, 2013 | 13.28B |
| March 31, 2013 | 14.21B |
| December 31, 2012 | 9.478B |
| September 30, 2012 | 14.04B |
| June 30, 2012 | 14.54B |
| March 31, 2012 | 13.91B |
| December 31, 2011 | 15.00B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.619B
Minimum
Dec 2021
13.94B
Maximum
Jun 2023
11.99B
Average
12.51B
Median
Revenue (Quarterly) Benchmarks
| Sandoz Group AG | -- |
| Roche Holding AG | -- |
| Amgen Inc | 8.196B |
| Incyte Corp | 1.013B |
| MorphoSys AG | 63.62M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 2.688B |
| Total Expenses (Quarterly) | 8.747B |
| EPS Diluted (Quarterly) | 1.31 |
| Enterprise Value | 218.04B |
| Gross Profit Margin (Quarterly) | 74.46% |
| Profit Margin (Quarterly) | 22.18% |
| Earnings Yield | 7.50% |
| Operating Earnings Yield | 5.25% |
| Normalized Earnings Yield | 4.523 |